Paltusotine in Carcinoid Syndrome

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

CLINICALTRIALS.GOV IDENTIFIER: NCT05361668

DRUG/TREATMENT: Paltusotine

PHASE: 2

STATUS: Recruiting

SPONSOR: Crinetics Pharmaceuticals Inc.

Dr. Aman Chauhan Discusses Paltusotine in Carcinoid Syndrome

UPDATE: On Sept 10, 2023, Crinetics Pharmaceuticals announced positive results for their paltusotine phase 3 acromegaly study. This is the same once-daily pill that is currently in a phase 2 study for NET patients with carcinoid syndrome. To read the announcement, go to https://crinetics.com/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/.

DESCRIPTION:

Crinetics is sponsoring a phase 2 study to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. For more information, go to LACNETS.CarcinoidStudy.com.

CONTACT:

Crinetics Clinical Trials

EMAIL: clinicaltrials@crinetics.com

PHONE: 833-827-9741